Similarly, in a study in a NASH mouse model, pemafibrate treatment did not reduce the total liver fat content, but it reduced F4/80-positive macrophage accumulation into the liver, ballooning degeneration of hepatocytes, and improved liver fibrosis, with a reduction in collagen 1α1 mRNA expression in the liver, and also decreased the ALT level and expression of pro-inflammatory genes.32 The gene discussed is GPT; the disease is Hepatic fibrosis.